Clinical Trials Logo

Filter by:
NCT ID: NCT00827606 Completed - Clinical trials for Familial Hypercholesterolemia

Atorvastatin Three Year Pediatric Study

Start date: March 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to characterize three year descriptive growth and development (ie, height, weight, body mass index, Tanner Stage) and efficacy of cholesterol reduction in pediatric subjects with Heterozygous Familial Hypercholesterolemia receiving atorvastatin treatment.

NCT ID: NCT00825955 Completed - Liver Cancer Clinical Trials

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

BRISK PS
Start date: February 17, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib

NCT ID: NCT00823992 Completed - Clinical trials for Diabetes Mellitus Type 2

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Start date: January 2009
Phase: Phase 3
Study type: Interventional

This 2 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to placebo in obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Patients will be randomized to receive taspoglutide (10mg sc once weekly for 4 weeks followed by 20mg once weekly) or placebo sc, in addition to their prescribed, pre-existing metformin therapy.After the first 24 weeks, patients on placebo will be switched to taspoglutide 20mg once weekly (after 4 weeks on taspoglutide 10mg once weekly) The anticipated time on study treatment is 12 months, and the target sample size is 100-500 individuals.

NCT ID: NCT00821977 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

Start date: November 2008
Phase: Phase 2/Phase 3
Study type: Interventional

This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.

NCT ID: NCT00814307 Completed - Clinical trials for Arthritis, Rheumatoid

A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

Start date: February 2009
Phase: Phase 3
Study type: Interventional

This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 Rheumatoid Arthritis studies.

NCT ID: NCT00811954 Completed - HIV Infection Clinical Trials

Comparative Study of Three NNRTI-Sparing HAART Regimens

Start date: May 2009
Phase: Phase 3
Study type: Interventional

The U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV infected patients who have never received anti-HIV therapy be treated with a triple drug regimen. The most commonly prescribed and successful regimen contains the medication efavirenz (EFV). However, this regimen may not be an option for everyone, hence alternative regimens are needed. This study was designed to look at how well different combinations of anti-HIV drugs work to decrease the amount of HIV in the blood (viral load) of and allow immune system recovery in people who have never received anti-HIV therapy. This study also examined drug tolerability and safety for the various drug combinations.

NCT ID: NCT00804986 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study for Patients With Type 2 Diabetes Mellitus

Start date: December 2008
Phase: Phase 2
Study type: Interventional

A multicenter, multinational, randomized,double-blind, placebo-controlled study in patients with Type 2 Diabetes Mellitus (T2DM). Patients with inadequate glycemic control using diet and exercise alone, or in combination with metformin, will be enrolled. The primary objective of this study is to test the hypothesis that LY2428757 given to patients with T2DM inadequately controlled with diet and exercise alone, or metformin monotherapy, produces a significant decrease in the mean hemoglobin A1c (HbA1c) from baseline to endpoint at 12 weeks as compared to placebo. Trial consists of 12 weeks of double-blind treatment and 4-week safety follow-up.

NCT ID: NCT00799877 Completed - Clinical trials for Chronic Plaque Psoriasis

Chronic Plaque Psoriasis (Ps) Registry

Start date: September 26, 2008
Phase:
Study type: Observational

The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).

NCT ID: NCT00797901 Completed - Major Depression Clinical Trials

Depression Treatment in General Medical Settings

Start date: August 2004
Phase: N/A
Study type: Interventional

The purpose of this study was to examine the effect of a new disease management model for depression, the Collaborative Depression Management Program (CDMP), designed to improve clinical outcomes and increase depression treatment in general medical settings.

NCT ID: NCT00791479 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

Start date: December 2008
Phase: Phase 2
Study type: Interventional

This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.